A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
Study sponsor: Enanta Pharmaceuticals, Inc · ENTA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-06-17Actual
Enrollment · participants142Actual
Source updated2025-10-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.